FDA says Pfizer Covid vaccine provides some protection after first dose, meets success criteria

The Food and Drug Administration said Tuesday data from Pfizer’s coronavirus vaccine trials was “consistent” with recommendations put forth by the agency for an emergency use authorization, adding the vaccine was highly effective and did not raise any specific safety concerns.

In briefing documents published ahead of an advisory meeting Thursday to review Pfizer’s vaccine, FDA staff also said data submitted appeared to show the vaccine provided protection after the first dose. Pfizer’s vaccine requires two doses about three weeks apart. Two doses of the vaccine were “highly effective” in preventing confirmed cases of Covid-19 at least seven days following the second dose, the agency…